PCV81 Cost-Effectiveness of Ticagrelor Versus Clopidogrel in Patients with Acute Coronary Syndrome: Results from the Plato Study: A Canadian Analysis  by Mittmann, N. et al.
Markov model for evaluating the long-term cost-effectiveness of clopidogrel in
patients with NSTEMI was adapted and extended by using local utility and eco-
nomic values. The effect of clopidogrel was applied during the first year in the
model and was estimated by the CURE trial. Costs assigned to each health state
included antiplatelet treatment cost, cost for the management of adverse events
and the costs for concomitant medication, hospitalization, outpatient visits, reha-
bilitation and nursing. The incremental cost-effectiveness ratio (ICER) was calcu-
lated. A probabilistic sensitivity analysis was conducted in order to assess the
impact of all uncertain model parameters varying simultaneously. The results are
presented as mean (95% Uncertainty Interval (UI)). RESULTS: The analysis showed
a discounted survival of 8.27 (8.25-8.30) years in the aspirin treatment group and
8.42 (8.39-8.44) years in the aspirinclopidogrel treatment group; a difference of
0.14 (0.11-0.18, p0.001) years. Adjusting the survival for the quality of life, the
model predicts 7.52 (7.15–7.79) and 7.66 (7.27–7.94) discounted QALYs in the aspirin
and clopidogrelaspirin arm, respectively, resulting in a difference of 0.14 QALYs
(0.10-0.17, p0.001). The cumulative lifetime costs per patient were € 15,976
(€14,848–€17.156) and € 15,392 (€14,301- €16,535), for aspirin and
clopidogrelaspirin treatment arm, respectively, a difference of € 584 (€525-€647).
The ICER was €4111 (€3342–€5169) for each life-year saved and €4385 (€3487–€5647)
for each QALY saved. For a decision threshold of €5500 per discounted QALY,
clopidogrelaspirin is cost-effective in more than 95% of randomly sampled
analyses. CONCLUSIONS: Treatment with clopidogrel in addition to aspirin is a
cost-effective treatment option in patients with NSTEMI from the perspective of a
third-party payer in Greece.
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OBJECTIVES: To estimate the cost-effectiveness of Dabigatran etexilate 150dib rel-
ative to Sintrom, Aspirin, Aspitin-Clopidogrel, Best Supportive Care and no treat-
ment, in the management of patients with Atrial Fibrillation in the Greek health
care setting. METHODS: A Markov model was adopted to estimate long term out-
comes of patients moving during their lifetime in between the following health
states: primary and recurrent ischemic stroke, hemorrhagic stroke, transient isch-
emic attack, systemic embolism, acute myocardial infarction, intracranial hemor-
rhage, extracranial hemorrhage and death. Data on event rates and patent quality
of life associated with different health states and patient survival times were based
on a multinational clinical trial (RE-LY) and the related literature. Furthermore,
data on resource use associated with the management of patients and of different
events were collected from a survey of local hospitals. Unit prices were collected
from official resources and relate to 2011. A 3.5% discount rate was used for all
outcomes. Sensitivity analysis and probabilistic analysis was used to test the ro-
bustness of the analysis RESULTS: The mean total life-time cost of patients on
Dabigatran etexilate was estimated at €20,103, relative to €11,639 in the case of
Sintrom, while mean Quality Adjusted Life Years (QALYs) were 9.86 and 9.83 for the
two treatments, respectively. The incremental cost-effectiveness ratio of Dabiga-
tran etexilate relative to Sintrom was estimated at €25,952. Similarly it was esti-
mated at €8,223, €10,392 and €7,536 against Asprin-Clopidogrel, Aspirin alone and
No-Tretament, respectively. Sensitivity analyses indicated that the cost-effective-
ness of Dabigatran etexilate remained below acceptable thresholds (€50,000 per
QALY gained) in significant variations of baseline parameters. Probabilistic analy-
sis indicated that in about 85% of cases its cost-effectiveness ratios, relative to the
above comparators were below the aforementioned threshold. CONCLUSIONS:
Dabigatran etexilate may represent a cost-effective choice for the management of
patients with atrial fibrillation in Greece.
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OBJECTIVES: To conduct an economic analysis comparing treatment with clopi-
dogrel against aspirin in patients with peripheral artery disease, a recent stroke, or
a recent myocardial infarction from the Greek third-party-payer perspective.
METHODS: A Markov model with a 6-month cycle length was developed to evalu-
ate the lifetime cost-effectiveness of clopidogrel versus aspirin. The effect of clopi-
dogrel was applied only during the first 2 years of the model and this was retrieved
from CAPRIE trial. Local utility data were used to estimate quality-adjusted life
years (QALY). The state-specific costs consists of the costs that reflect and encap-
sulate all resource used for the care of patients within the health care system
during a 6-month period in the acute and follow-up phase, separately. The cost-
effectiveness of clopidogrel over aspirin was evaluated by calculating the incre-
mental cost per life year saved (LYS) and incremental cost per QALY saved (ICER). A
probabilistic sensitivity analysis was conducted and the results are presented as
mean (95% Uncertainty Interval (UI)). RESULTS: The analysis showed that the dis-
counted survival was 11.83 (11.41-12.22) years and 12.17 (11.75-12.55) years in as-
pirin and clopidogrel treatment group, respectively, a difference of 0.27 (0.10-0.45)
life-years. The corresponding discounted QALYs were 8.63 (8.34 – 8.91) and 8.84
(8.54–9.10), respectively. The cumulative lifetime costs per patient were €19,880
(€18,863–€20,939) and €21,039 (€20,006–€22,089), for aspirin and clopidogrel treat-
ment arm, respectively. The ICER was calculated to be € 4,921 (€ 3,079–€ 9,969) for
each LYS and €6,326 (€ 3,737–€ 16,699) for each QALY saved. For a “willigness-to-
pay” threshold of € 9,500 per discounted QALY, clopidogrel was found to be cost-
effective in more than 90% of randomly sampled analyses. CONCLUSIONS: This
economic analysis indicates that treatment with clopidogrel for secondary preven-
tion of cardiovascular events in atherothrombotic patients is a cost-effective anti-
platelet treatment over aspirin in a Greek third-party payer perspective.
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OBJECTIVES: To evaluate common therapeutic alternatives (rosuvastatin, atorvas-
tatin, simvastatin, pravastatin) for the prevention of primary and secondary car-
diovascular events in Greece. METHODS: A Markov model with distinct health
states (no event, fatal/non fatal acute myocardial infarction (MI), fatal/non fatal
stroke, post-MI, post-stroke & all cause death) was developed, to reflect within a
20-year time span health and economic outcomes of non-smoking patients as-
sumed to be at base line at mean age of 70 years, with no prior treatment of
hypertension, systolic blood pressure at 140mmHg and total cholesterol at 260mg/
Dl. The HellenicSCORE risk score equation was used to transform systolic blood
pressure reductions in different medications into long-term reductions in cardio-
vascular events. Transition probabilities from acute myocardial infarction or
stroke to death were obtained from the Framingham study. Treatment cost was
estimated from a payer perspective and includes the cost of medication and all
resources used in the management of events. Health states were associated with
local quality of life data to estimate Quality Adjusted Life Years (QALYs). A proba-
bilistic sensitivity analysis was conducted to deal with uncertainty. Prices reflect
2011 and outcomes were discounted at 3.5%. RESULTS: For males, discounted
QALYs were: 10.18 (95%CI:10.11-10.23), 10.04 (95%CI:9.96-10.10), 9.94 (95%CI: 9.84-
10.02) and 9.88 (95%CI: 9.76-9.97) for rosuvastatin, atorvastatin, simvastatin and
pravastatin, respectively. The mean total cost was: 15,646 (95%CI:15,173-16,130),
16,678 (95%CI:16,184-17,187), 17,242 (95%CI:16,732-17,766) and 17,585 (95%CI:
17,060-18,119) respectively. For females, QALYs were: 10.33 (95%CI:10.28-10.37),
10.26 (95%CI:10.20-10.30), 10.20 (95%CI:10.13-10.25) and 10.16 (95%CI: 10.08-10.22),
respectively. Similarly, mean total cost was: 15,030 (95%CI:14,632-15,430), 15,608
(95%CI:15,192-16,023), 15,951 (95%CI:15,521-16,379) and 16,153 (95%CI:15,714-
16,591) respectively. Hence rosuvastatin was a dominant therapy option.
CONCLUSIONS: Rosuvastatin may represent an attractive option relative to alter-
native therapies, from an economic and clinical point of view, in the primary and
secondary prevention of cardiovascular events in the National Health Service of
Greece.
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OBJECTIVES: The cost-effectiveness study of pravastatin for primary prevention of
coronary artery disease (CAD) was assessed applying epidemiologic data and risk
predictions of CAD in Japan. METHODS: A Markov transition model was used for
evaluating the cost-effectiveness of 20mg/day of pravastatin treatment with diet
therapy. The incidence of acute myocardial infarction (AMI) was estimated using
newly developed risk predictions of CAD in Japan. Hypothetical population of men
and women from 45 to 75 years old were assumed according to the cardiac risk
factors from Japan Atherosclerosis Society Guideline for Prevention of Atheroscle-
rotic Cardiovascular Disease. Quality-adjusted life-years (QALYs) and incremental
cost-effectiveness ratios (ICERs) over a lifetime horizon were estimated from the
perspective of payers. One way sensitivity analysis and probabilistic sensitivity
analysis were conducted to see the robustness of the model. RESULTS: The pre-
dicted incidence of AMI was 4.4/10,000 person-years for men and 1.4/10,000 per-
son-years for women aged 55 years with initial total cholesterol level (TC) of 240
mg/dl without other cardiac risk factors (i.e. low cardiac risk) and 20.1/10,000 per-
son-years for men and 6.6/10,000 person-years for women with initial TC level of
240 mg/dl, and risks of smoking, hypertension and diabetes (i.e. high cardiac risk).
Over a lifetime horizon, the ICERs were depended on the level of cardiac risk fac-
tors. The ICERs were decreased proportionally with increased age and number of
cardiac risk factors. Considering the willingness to pay threshold per QALYs, prav-
astatin treatment was not cost-effective in all subgroups evaluated in this study.
CONCLUSIONS: Due to the predicted low incidence of CAD in Japan, pravastatin
treatment was not cost-effective for primary prevention of CAD in population not
only at low cardiac risk but also at high cardiac risk. Further evaluations of cost-
effectiveness on CAD treatment in Japan using available epidemiological data and
risk predictions are needed.
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OBJECTIVES: Ticagrelor, co-administered with acetylsalicylic acid, is a new anti-
platelet therapy for patients with acute coronary syndrome (ACS) aimed at pre-
venting thrombotic events [i.e., cardiovascular mortality, myocardial infarction
(MI) and stroke]. The goal was to determine the cost per life year gained (LYG) for
ticagrelor compared to current standard therapy (clopidogrel) using a cost-effec-
tiveness analysis framework based on the published results from the Platelet In-
hibition and Patient Outcomes (PLATO). METHODS: A Markov model framework
was developed in order to evaluate the costs and benefits of ticagrelor over a life-
time time horizon. The clinical outcomes consisted of four health states: “MI”,
“Stroke”, “All Cause Mortality” and “Recovered”, with frequencies derived from the
pivotal PLATO study at one year. These health states were extrapolated into the
future via “Live” and “Die” scenarios. Resources and costs (2010 Canadian $) were
obtained from the literature or public domain. A 5% discount rate was applied to all
the cost and clinical inputs after the first year. RESULTS: An incremental cost
effectiveness ratio (ICER) of $1125/LYG was determined. Probabilistic sensitivity
analysis presented greater than 99% of all iterations resulting in an ICER less than
$50,000/LYG. The economic model was most sensitive to the probability of death
within one year of ticagrelor or clopidogrel treatment. CONCLUSIONS: Based on
outcomes in the PLATO trial, the use of ticagrelor instead of clopidogrel for treat-
ment of ACS in Canada is associated with an ICER of $1,125/LYG.
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SIMULATION OF LONG-TERM CLINICAL BENEFITS AND COSTS OF ADD-ON
THERAPY WITH ALISKIREN IN HYPERTENSIVE PATIENTS WITH DIABETIC
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OBJECTIVES: Diabetic nephropathy significantly increases the risk of cardiovascu-
lar disease (CVD) and end-stage renal disease (ESRD) in hypertensive patients.
According to the AVOID study, the direct renin-inhibitor aliskiren, when added to
losartan and optimal antihypertensive therapy in patients with hypertension, type
2 diabetes (T2DM) and diabetic nephropathy, significantly (p0.001) reduced albu-
minuria by 20% over 6 months, as assessed by urinary albumin-creatinine ratio
(UACR). This simulation examines the potential long-term clinical benefits and
costs of add-on therapy with aliskiren in hypertensive patients with T2DM and
diabetic nephropathy in Germany. METHODS: We developed a micro-simulation
model to depict the progression to ESRD, measured by UACR levels over time.
Patients at model entry were on maximal recommended doses of losartan and
optimal antihypertensive therapy, and either continued this regimen or received
aliskiren as an add-on therapy. In scenario analyses, different assumptions on the
maintenance of the 20% UACR-reduction were made. Expected costs of pharmaco-
therapy and medical care were calculated based on German-specific sources over
10 years applying an annual discount rate of five percent. Sensitivity analyses were
conducted to analyze the impact of different input parameters. RESULTS: Add-on
therapy with aliskiren was projected to reduce the risk of ESRD by 1.8% and delay
the onset of ESRD by 0.15 years assuming that the effects of aliskiren on UACR-
reduction are maintained over 5 years. While discounted costs of pharmacother-
apy were estimated to increase by 1762€ per patient with aliskiren, costs of ESRD-
related care were estimated to decrease by 3804€ over this same period, yielding
total cost savings. Findings were sensitive to the duration over which the benefits
of add-on therapy with aliskiren were assumed to be maintained. CONCLUSIONS:
In hypertensive patients with T2DM and diabetic nephropathy receiving losartan
and optimal antihypertensive therapy, add-on therapy with aliskiren is projected
to yield clinical benefits and cost savings.
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A COST-EFFECTIVENESS ANALYSIS OF TICAGRELOR IN PATIENTS WITH ACUTE
CORONARY SYNDROME IN GREECE
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OBJECTIVES: To evaluate the cost-effectiveness of a one-year treatment period
with 90 mg twice daily Ticagrelor compared to 75 mg/day Clopidogrel in acute
coronary syndrome (ACS) patients with or without ST-segment elevation from the
third-party-payer perspective in Greece. METHODS: An existing model consisting
of a one-year decision tree based on the PLATO trial data and a long-term extrap-
olation Markov model was adapted to the Greek health-care setting. Utility values
obtained from the PLATO trial were used to estimate quality-adjusted life years
(QALY) for both the decision tree and the Markov model. Local unit costs in com-
bination with resource use data collected within the PLATO trial were used to
estimate the costs incorporated in the analysis. These costs included treatment
and medication costs, cost for the management of adverse events, hospitalization,
outpatient visits, rehabilitation and nursing costs. Cost-effectiveness and cost-
utility was expressed as the incremental cost per life year gained (LYG) and QALY
gained (ICER), respectively. RESULTS: Implementing a lifetime horizon, the analy-
sis predicts a discounted survival of 11.63 years in the Ticagrelor treatment group
and 11.48 years in the Clopidogrel treatment group. The corresponding discounted
QALYs were 9.78 and 9.65, respectively. The cumulative lifetime costs per patient
were €24,967 and €24,170, for Ticagrelor and Clopidogrel treatment arm, respec-
tively. The ICER was €5239 for each LYG and €6079 for each QALY saved. Imple-
menting a 5-year horizon analysis, results in a discounted survival of 4.36 and 4.31
years for Ticagrelor and Clopidogrel treatment respectively. The QALYs and costs
per patient were 3.77 and €15,239 for Ticagrelor and 3.73 and €14,604 for Clopi-
dogrel. The ICER in this case was €12,631 for each LYG and €14,176 for each QALY
saved. CONCLUSIONS:One-year treatment with Ticagrelor in addition to aspirin is
a cost-effective treatment option vs Clopidogrel plus aspirin in patients with ACS in
Greece.
PCV84
RESOURCE UTILIZATION AND COSTS FOR CANDESARTAN IN HEART FAILURE:
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OBJECTIVES: Chronic heart failure (HF) is a major cause of morbidity and mortality
and a growing burden to the healthcare system. The objective was to assess the
cost-effectiveness of candesartan cilexetil, an angiotensin II type 1 receptor blocker
(ARB) for the treatment of HF in the Austrian setting. METHODS: A pre-specified
economic evaluation was conducted on resource utilization prospectively col-
lected alongside the CHARM programme. We examined the effect of adding can-
desartan in all 7599 patients randomized. All patients were considered to have
been managed in Austria. Our analysis takes the perspective of a third party payer.
CHARM consisted of a series of parallel randomized clinical trials comparing can-
desartan with placebo (standard therapy) in patients with NYHA Class II-IV HF: -
CHARM-Alternative (LVEF 40% patients not receiving ACE inhibitors because of
previous intolerance); - CHARM-Added (LVEF 40% patients currently receiving
ACE inhibitors); - or CHARM-Preserved (LVEF  40% patients). Primary outcome of
the overall programme: all-cause mortality; for the component trials: composite of
cardiovascular death and hospital admission for HF. Resource use was collected
prospectively on drug treatment, patients admitted to hospital, admissions for
cardiovascular reasons, and procedures/operations. These data were used to de-
termine the additional direct costs incurred, and potential savings made with can-
desartan. Unit costs were elicited from published Austrian sources in accordance
with local guidelines. 2008 was chosen as the price year. RESULTS: Adjunctive
treatment with candesartan in CHARMAlternative and CHARM-Added led to clin-
ical benefits and, depending on the trial, to either cost savings or low additional
costs. CONCLUSIONS: Not only does candesartan improve all important clinical
outcomes in HF but also offers these benefits at little or no additional cost to the
health care system; indeed, its use in patients with HF and reduced LV systolic
function may lead to an actual reduction in the direct costs of healthcare in Austria.
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OBJECTIVES: Increasing real-life adherence to statin therapy is important to
achieve the clinical benefits of reducing cardiovascular events (CVEs) reported in
randomized clinical trials (RCTs). The aim of this pilot study was to determine the
cost-effectiveness of a pharmaceutical care intervention program in community
pharmacies, aimed to increase statin adherence for the secondary prevention of
CVEs. METHODS: Meta-analyses of five RCTs were performed to determine the
clinical efficacy of statins for secondary prevention, adjusted for different levels of
therapy adherence. A Markov model with a lifelong time horizon was developed to
estimate the influence of statin adherence on CVEs: stroke, myocardial infarction
(MI), revascularization and mortality. Baseline adherence was calculated in a large
Dutch prescription database, using the proportion of days covered (PDC) method.
The effect of pharmacists’ interventions on statin adherence was derived from
literature. A Dutch health care provider’s perspective was adopted; costs and ef-
fects were discounted at 4.0% and 1.5% per annum, respectively. RESULTS: Adher-
ence to statin therapy for secondary prevention in The Netherlands was 73.0%. In
a cohort of 1000 patients, a 7% increase in adherence resulted in a reduction of 1.9
non-fatal strokes, 0.5 fatal strokes, 7.9 non-fatal MIs, 3.7 fatal MIs and 9.1 revascu-
larizations. Additional medication and intervention costs in the intervention group
were €56,000; the cost-savings due to reduced CVEs were €109,000. Overall, the
pharmaceutical care program resulted in 53 quality-adjusted life years (QALYs)
gained and cost-savings of €53,000. CONCLUSIONS: Pharmaceutical care programs
in community pharmacies can improve statin adherence for secondary prevention
of CVEs. At a reasonable level of intervention effectiveness, the programs resulted
in both clinical benefits and cost-savings. The model developed in this pilot study
will be used to estimate the cost-effectiveness of a pharmaceutical care program
(the MeMO intervention) in the The Netherlands that is currently under clinical
evaluation.
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LONG-TERM COST-EFFECTIVENESS ANALYSIS OF TICAGRELOR IN PATIENTS
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OBJECTIVES: The multicentre, double-blind, randomized PLATO trial showed that
treatment with ticagrelor  aspirin reduced the risk of myocardial infarction,
stroke or death from vascular causes without a significant increase in major bleed-
ing compared to clopidogrel  aspirin treatment in patients with ACS. The long-
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